Surrozen, Inc./DE Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period
Surrozen, Inc./DE (SRZN) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period of 5.00 thousand shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod · last filed 2026-08-06
- Surrozen, Inc./DE share-based compensation arrangement by share-based payment award, options, expirations in period for the quarter ending 2025-12-31 was 15.00K shares.
- Surrozen, Inc./DE share-based compensation arrangement by share-based payment award, options, expirations in period for the quarter ending 2025-09-30 was 11.00K shares, a 83.33% increase year-over-year.
- Surrozen, Inc./DE share-based compensation arrangement by share-based payment award, options, expirations in period for the quarter ending 2025-06-30 was 6.00K shares.
- Surrozen, Inc./DE share-based compensation arrangement by share-based payment award, options, expirations in period for the quarter ending 2025-03-31 was 4.00 shares, a 99.60% decline year-over-year.
- Surrozen, Inc./DE share-based compensation arrangement by share-based payment award, options, expirations in period for fiscal 2025 was 32.00K shares, a 319900.00% increase from fiscal 2024.
- Surrozen, Inc./DE share-based compensation arrangement by share-based payment award, options, expirations in period for fiscal 2024 was 10.00 shares, a 60.00% decline from fiscal 2023.
- Surrozen, Inc./DE share-based compensation arrangement by share-based payment award, options, expirations in period for fiscal 2023 was 25.00 shares, a 47.06% increase from fiscal 2022.
- Surrozen, Inc./DE share-based compensation arrangement by share-based payment award, options, expirations in period for fiscal 2022 was 17.00 shares, a 99.97% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 12 month |
|---|---|---|---|---|
| 2026-06-30 | 5.00K shares 10-Q · filed 2026-08-06 | |||
| 2025-12-31 | 15.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | 26.00K shares derived: sum of 2 quarters · filed 2026-03-23 | 32.00K shares derived: sum of 3 quarters · filed 2026-03-23 | 32.00K shares 10-K · filed 2026-03-23 |
| 2025-09-30 | 11.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | 17.00K shares derived: sum of 2 quarters · filed 2025-11-07 | 17.00K shares 10-Q · filed 2025-11-07 | 10.01K shares derived: sum of 4 quarters · filed 2025-11-07 |
| 2025-06-30 | 6.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-08 | 6.00K shares 10-Q · filed 2025-08-08 | -990.00 shares derived: sum of 3 quarters · filed 2025-08-08 | 5.01K shares derived: sum of 4 quarters · filed 2025-08-08 |
| 2025-03-31 | 4.00 shares 10-Q · filed 2025-05-09 | -6.99K shares derived: sum of 2 quarters · filed 2025-05-09 | -986.00 shares derived: sum of 3 quarters · filed 2025-05-09 | -986.00 shares derived: sum of 4 quarters · filed 2025-05-09 |
| 2024-12-31 | -6.99K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | -990.00 shares derived: sum of 2 quarters · filed 2025-03-31 | -990.00 shares derived: sum of 3 quarters · filed 2025-03-31 | 10.00 shares 10-K · filed 2025-03-31 |
| 2024-09-30 | 6.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | 6.00K shares derived: sum of 2 quarters · filed 2024-11-06 | 7.00K shares 10-Q · filed 2024-11-06 | -289.98K shares derived: sum of 4 quarters · filed 2024-11-06 |
| 2024-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | 1.00K shares 10-Q · filed 2024-08-12 | -295.98K shares derived: sum of 3 quarters · filed 2024-08-12 | -245.97K shares derived: sum of 4 quarters · filed 2024-08-12 |
| 2024-03-31 | 1.00K shares 10-Q · filed 2024-05-08 | -295.98K shares derived: sum of 2 quarters · filed 2024-05-08 | -245.97K shares derived: sum of 3 quarters · filed 2024-05-08 | 1.02K shares derived: sum of 4 quarters · filed 2024-05-08 |
| 2023-12-31 | -296.98K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-10 | -246.97K shares derived: sum of 2 quarters · filed 2024-04-10 | 24.00 shares derived: sum of 3 quarters · filed 2024-04-10 | 25.00 shares 10-K · filed 2024-04-10 |
| 2023-09-30 | 50.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | 297.00K shares derived: sum of 2 quarters · filed 2023-11-08 | 297.00K shares 10-Q · filed 2023-11-08 | 297.00K shares derived: sum of 4 quarters · filed 2023-11-08 |
| 2023-06-30 | 247.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | 247.00K shares 10-Q · filed 2023-08-09 | 247.00K shares derived: sum of 3 quarters · filed 2023-08-09 | 247.01K shares derived: sum of 4 quarters · filed 2023-08-09 |
| 2023-03-31 | 1.00 shares 10-Q · filed 2023-05-10 | 6.00 shares derived: sum of 2 quarters · filed 2023-05-10 | 9.00 shares derived: sum of 3 quarters · filed 2023-05-10 | -7.00 shares derived: sum of 4 quarters · filed 2023-05-10 |
| 2022-12-31 | 5.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | 8.00 shares derived: sum of 2 quarters · filed 2023-03-31 | -8.00 shares derived: sum of 3 quarters · filed 2023-03-31 | 17.00 shares 10-K · filed 2023-03-31 |
| 2022-09-30 | 3.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | -13.00 shares derived: sum of 2 quarters · filed 2022-11-14 | 12.00 shares 10-Q · filed 2022-11-14 | 4.75K shares derived: sum of 4 quarters · filed 2022-11-14 |
| 2022-06-30 | -16.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | 9.00 shares 10-Q · filed 2022-08-11 | 4.75K shares derived: sum of 3 quarters · filed 2022-08-11 | |
| 2022-03-31 | 25.00 shares 10-Q · filed 2022-05-11 | 4.77K shares derived: sum of 2 quarters · filed 2022-05-11 | ||
| 2021-12-31 | 4.74K shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-28 | 60.08K shares 10-K · filed 2022-03-28 | ||
| 2021-09-30 | 55.33K shares 10-Q · filed 2021-11-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B |